Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Cipher Secures Summary Judgment in the Company’s Favor in Pending Patent Litigation Involving CIP-TRAMADOL ER

By Pharmaceutical Processing | January 4, 2010

Cipher PharmaceuticalsInc. today announced a final judgment hasbeen entered in favour of Cipher in relation to pending patent litigation withPurdue Pharma Products L.P. and Napp Pharmaceutical Group Ltd. (together”Purdue”) in the United States District Court for the Eastern District ofVirginia. The patent litigation involves the company’s New DrugApplication, filed with the FDA,for CIP-TRAMADOL ER, an extended-release tramadol product. The Cipher Judgmentterminates any further stay of FDA approval of Cipher’s NDA under theapplicable provisions of the Hatch-Waxman Act. Cipher plans to move forward toobtain FDA final approval as part of its broader CIP-TRAMADOL ERcommercialization strategy. The company continues to conduct ongoingdiscussions with potential commercial partners interested in licensingCIP-TRAMADOL ER. The final judgment in favour of Cipher holds that the patents-in-suit areinvalid for obviousness based on a prior decision of the United StatesDistrict Court for the District of Delaware, dated August 14, 2009,invalidating the Orange Book-listed patents for Ultram(R) ER in litigationfiled by Purdue against Par Pharmaceutical, Inc. That decision in thePar litigation is currently under appeal before the United States Court ofAppeals for the Federal Circuit. Cipher anticipates that Purdue may appeal theCipher Judgment as well, though Purdue has not yet done so. Cipher filed a revised NDA for CIP-TRAMADOL ER in Q2 2008, and receivedtentative FDA approval in February 2009. In Q3 2009, the Company filed aParagraph IV Certification with the FDA, which states that the relevant patentlisted in the FDA’s “Orange Book” for Ultram(R) ER is invalid, unenforceable,and/or will not be infringed by the manufacture or sale of Cipher’s drugproduct. Under the applicable provisions of the Hatch-Waxman Act, this patentchallenge can delay or stay final FDA approval of Cipher’s NDA by 30 months,or until the patent challenge is resolved, whichever occurs first. The CipherJudgment terminates any further stay of Cipher’s NDA under the applicableprovisions of the Hatch-Waxman Act.

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards